MedTrace Logo

Open Label Placebo in the Treatment of Low Back Pain

NCT02022124 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 83

Last updated 2016-01-22

No results posted yet for this study

Summary

Patients will be randomized to receive open-label (honestly described placebo) immediately at baseline or be eligible to receive the open-label treatment three weeks after the baseline measurements. Therefore all patients will be eligible to receive open-label placebo treatment for their chronic low back pain during the course of the study.

Conditions

  • Chronic Low Back Pain

Interventions

DRUG

Microcrystalline cellulose (open-label inert substance)

The intervention will be an inert substance, microcrystalline cellulose in a capsule. Participants will take two capsules daily.

Sponsors & Collaborators

  • Hospital de Egas Moniz

    lead OTHER

Principal Investigators

  • Claudia Carvalho, PhD · ISPA - Instituto Universitario de Ciencias Psicologicas, Sociais e da Vida

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-11-30
Primary Completion
2015-12-31
Completion
2015-12-31

Countries

  • Portugal

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02022124 on ClinicalTrials.gov